ArticleCurrent medical science2025
Associations Between Gut Microbiota, Short-Chain Fatty Acids, and High-Salt Diet-Induced Hypertension in Rats.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The role and mechanisms of gut microbiota in blood pressure regulation and cardiovascular health in hypertensive patients: an intervention study based on probiotics and high-fiber diets.Frontiers in cardiovascular medicine · 2026Article
- Salt sensitivity potentiates high-salt diet-induced intestinal barrier disruption and gut microbiome dysbiosis in rats.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveNumerous studies have established a link between hypertension (HTN) and a high-salt diet (HSD). However, the precise mechanisms are still being investigated, with increasing evidence suggesting that HSD can alter the gut microbiome balance, influence the production of microbiome metabolites and potentially lead to high blood pressure, presenting a promising avenue for targeting specific microbiota in HTN treatment. Short-chain fatty acids (SCFAs) are produced by gut bacteria and are associated with blood pressure regulation. Thus, the relationships among HSD, SCFAs, and blood pressure could provide valuable information on the pathophysiology of HTN. This study aimed to assess the impact of HSD on HTN by investigating its influence on the gut microbiota composition and SCFA levels in a rat model of HTN.
methodsThe HTN rat model was constructed by placing the rats on HSD (8% NaCl) for 8 weeks. On the 8th week, fecal samples were collected from the rats for DNA extraction. The profile of the gut microbiota was subsequently evaluated through 16S rRNA sequencing. The fecal SCFAs were subsequently measured and analyzed.
resultsAnalysis of 16S rRNA sequencing data revealed that consumption of HSD was associated with an increase in pathogenic bacteria, including Turicibacter and Clostridia_UCG-014, and a decrease in beneficial bacteria, including Bifidobacterium and Lactobacillus. Metabolomic analysis of fecal samples suggested that HSD could increase the concentrations of most SCFAs, except caproic acid. Notably, a significant correlation was observed through Spearman correlation analysis between SCFAs and the changes in the gut microbiota caused by HSD, leading to a direct effect on SCFA levels.
conclusionThe alterations in the gut microbiota resulting from HSD impact the levels of SCFAs, potentially disrupting gut equilibrium and initiating HTN, thereby increasing susceptibility to cardiovascular disease and associated health complications.
Indexed as
Identifiers
40676312What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.